1. Home
  2. SWAG vs IGC Comparison

SWAG vs IGC Comparison

Compare SWAG & IGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Stran & Company Inc.

SWAG

Stran & Company Inc.

HOLD

Current Price

$1.66

Market Cap

28.2M

ML Signal

HOLD

Logo IGC Pharma Inc.

IGC

IGC Pharma Inc.

HOLD

Current Price

$0.32

Market Cap

31.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SWAG
IGC
Founded
1994
2005
Country
United States
United States
Employees
156
N/A
Industry
Advertising
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
28.2M
31.5M
IPO Year
N/A
2005

Fundamental Metrics

Financial Performance
Metric
SWAG
IGC
Price
$1.66
$0.32
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$5.25
AVG Volume (30 Days)
37.9K
1.0M
Earning Date
05-14-2026
03-19-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
59.09
EPS
N/A
N/A
Revenue
N/A
$1,271,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$13.06
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.01
$0.24
52 Week High
$3.50
$0.50

Technical Indicators

Market Signals
Indicator
SWAG
IGC
Relative Strength Index (RSI) 51.07 54.26
Support Level $1.59 $0.28
Resistance Level $1.84 $0.44
Average True Range (ATR) 0.10 0.02
MACD 0.00 -0.00
Stochastic Oscillator 50.00 39.26

Price Performance

Historical Comparison
SWAG
IGC

About SWAG Stran & Company Inc.

Stran & Co Inc is an outsourced marketing solutions provider, working closely with customers to develop sophisticated marketing programs that leverage promotional products and loyalty incentive expertise. In addition to selling branded products, it offers its clients custom sourcing capabilities, which is a flexible and customizable e-commerce solution for promoting branded merchandise and other promotional products, managing promotional loyalty and incentives, print collateral, event assets, order and inventory management, and designing and hosting online retail pop-up shops. The company's segment consists of the Stran segment and the SLS segment. The company generates the majority of its revenue from the Stran segment.

About IGC IGC Pharma Inc.

IGC Pharma Inc develops cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome, and chronic pain. The company has investigational drug assets targeting Alzheimer's disease, IGC-AD1, IGC-M3, IGC-1C, and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles.

Share on Social Networks: